Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East,… Read more
Island Pharmaceuticals Ltd (ILA) - Net Assets
Latest net assets as of June 2025: AU$7.16 Million AUD
Based on the latest financial reports, Island Pharmaceuticals Ltd (ILA) has net assets worth AU$7.16 Million AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$7.49 Million) and total liabilities (AU$336.43K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$7.16 Million |
| % of Total Assets | 95.51% |
| Annual Growth Rate | N/A |
| 5-Year Change | 11.84% |
| 10-Year Change | N/A |
| Growth Volatility | 176.73 |
Island Pharmaceuticals Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Island Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Island Pharmaceuticals Ltd (2019–2024)
The table below shows the annual net assets of Island Pharmaceuticals Ltd from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | AU$7.16 Million | +371.19% |
| 2023-12-31 | AU$1.52 Million | -14.93% |
| 2022-12-31 | AU$1.79 Million | -58.65% |
| 2021-12-31 | AU$4.32 Million | -32.52% |
| 2020-12-31 | AU$6.40 Million | +974084.78% |
| 2019-12-31 | AU$-657.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Island Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2508421700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$31.63 Million | 441.97% |
| Other Comprehensive Income | AU$611.37K | 8.54% |
| Total Equity | AU$7.16 Million | 100.00% |
Island Pharmaceuticals Ltd Competitors by Market Cap
The table below lists competitors of Island Pharmaceuticals Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KB No.2 Special Purpose Acq
KQ:192250
|
$28.13 Million |
|
Gowing Bros Ltd
AU:GOW
|
$28.14 Million |
|
Hauman Technologies
TWO:6218
|
$28.15 Million |
|
MoneyHero Limited Class A Ordinary Shares
NASDAQ:MNY
|
$28.15 Million |
|
Spring Valley Acquisition Corp. II Class A Ordinary Shares
NASDAQ:SVII
|
$28.11 Million |
|
ORIENTBIO Inc.
KO:002630
|
$28.10 Million |
|
Yibitas Yozgat Isci Birligi Insaat Malzemeleri Ticaret Sanayi AS
IS:YBTAS
|
$28.10 Million |
|
Revivegen Co., Ltd.
TWO:7578
|
$28.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Island Pharmaceuticals Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,518,847 to 7,156,601, a change of 5,637,754 (371.2%).
- Net loss of 3,920,139 reduced equity.
- Share repurchases of 9,053,790 reduced equity.
- Other comprehensive income increased equity by 286,283.
- Other factors increased equity by 18,325,400.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-3.92 Million | -54.78% |
| Share Repurchases | AU$9.05 Million | -126.51% |
| Other Comprehensive Income | AU$286.28K | +4.0% |
| Other Changes | AU$18.33 Million | +256.06% |
| Total Change | AU$- | 371.19% |
Book Value vs Market Value Analysis
This analysis compares Island Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | AU$0.00 | AU$0.40 | x |
| 2020-12-31 | AU$0.07 | AU$0.40 | x |
| 2021-12-31 | AU$0.05 | AU$0.40 | x |
| 2022-12-31 | AU$0.02 | AU$0.40 | x |
| 2023-12-31 | AU$0.02 | AU$0.40 | x |
| 2024-12-31 | AU$0.04 | AU$0.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Island Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3296.73%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.05x
- Recent ROE (-54.78%) is above the historical average (-82.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-592.30 |
| 2020 | -33.24% | 0.00% | 0.00x | 1.04x | AU$-2.77 Million |
| 2021 | -60.37% | 0.00% | 0.00x | 1.13x | AU$-3.04 Million |
| 2022 | -158.54% | -25580.20% | 0.01x | 1.15x | AU$-3.01 Million |
| 2023 | -188.59% | -228.86% | 0.49x | 1.69x | AU$-3.02 Million |
| 2024 | -54.78% | -3296.73% | 0.02x | 1.05x | AU$-4.64 Million |
Industry Comparison
This section compares Island Pharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $31,815,679
- Average return on equity (ROE) among peers: -60.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Island Pharmaceuticals Ltd (ILA) | AU$7.16 Million | 0.00% | 0.05x | $28.12 Million |
| Adalta Ltd (1AD) | $2.03 Million | -265.03% | 1.74x | $171.91K |
| Algorae Pharmaceuticals Ltd (1AI) | $2.88 Million | -33.65% | 0.18x | $9.99 Million |
| ACRUX Ltd (ACR) | $17.49 Million | -17.99% | 0.05x | $2.16 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $11.42 Million |
| Arovella Therapeutics Ltd (ALA) | $11.23 Million | -77.89% | 0.18x | $39.76 Million |
| Anatara Lifesciences Ltd (ANR) | $5.92 Million | -48.49% | 0.08x | $718.75K |
| Bio-Gene Technology Ltd (BGT) | $4.25 Million | -56.43% | 0.18x | $2.33 Million |
| BTC Health Ltd (BTC) | $11.34 Million | -4.81% | 0.03x | $364.22 |
| Cambium Bio Ltd (CMB) | $8.27 Million | -79.86% | 0.16x | $8.11 Million |
| Clinuvel Pharmaceuticals Ltd (CUV) | $240.81 Million | 15.02% | 0.13x | $251.65 Million |